Add Company
Join Now

Evergreen Theragnostics Revenue and Competitors

License our Company Data API

Location

#4969

Growjo Ranking

Pharma

Industry
Embed

Estimated Revenue & Valuation

  • Evergreen Theragnostics's estimated annual revenue is currently $27.9M per year.(i)
  • Evergreen Theragnostics's estimated revenue per employee is $242,948

Employee Data

  • Evergreen Theragnostics has 115 Employees.(i)
  • Evergreen Theragnostics grew their employee count by 40% last year.

Evergreen Theragnostics's People

NameTitleEmail/Phone
1
Chief Financial OfficerReveal Email/Phone
2
Chief Scientific OfficerReveal Email/Phone
3
VP, Manufacturing and Radiation Safety OfficerReveal Email/Phone
4
Head QualityReveal Email/Phone
5
Head Product ManagementReveal Email/Phone
6
Director Market AccessReveal Email/Phone
7
Director Discovery Strategy and Business DevelopmentReveal Email/Phone
8
Director PharmacologyReveal Email/Phone
9
Director, CDMO Business DevelopmentReveal Email/Phone
10
Director Regulatory AffairsReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$6.6M3332%N/AN/A
#2
$38M1896%N/AN/A
#3
$6.6M3322%N/AN/A
#4
$4180M152421%$550MN/A
#5
$17.5M8750%N/AN/A
#6
$6.7M125-37%$199.6MN/A
#7
$10.9M5415%N/AN/A
#8
$15.3M7633%N/AN/A
#9
$128.6M64016%N/AN/A
#10
$18.7M9321%N/AN/A
Add Company

What Is Evergreen Theragnostics?

Evergreen Theragnostics was established in 2019 to be a leading US-based radiopharmaceutical Contract Development and Manufacturing Organization (CDMO). Our team’s expertise and track record in theragnostic radiopharmaceutical commercialization, manufacturing process development, and regulatory affairs management, make us your ideal partner for all of your radiopharmaceutical development, manufacturing, and commercialization needs.

keywords:N/A

N/A

Total Funding

115

Number of Employees

$27.9M

Revenue (est)

40%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$24M11754%N/A
#2
$17.3M11970%N/A
#3
$19.4M121-26%N/A
#4
$33.3M12231%N/A
#5
$31.1M1239%N/A